Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience

Micro-Abstract Data are limited regarding outcomes in patients with end-stage renal disease (ESRD) and metastatic renal cell carcinoma (mRCC) receiving targeted therapy. We retrospectively identified patients with mRCC and ESRD treated at the University of Texas M.D. Anderson Cancer Center from 2002...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2014-10, Vol.12 (5), p.348-353
Hauptverfasser:	Shetty, Aditya V, Matrana, Marc R, Atkinson, Bradley J, Flaherty, Amber L, Jonasch, Eric, Tannir, Nizar M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Disease-Free Survival Everolimus Female Hematology, Oncology and Palliative Medicine Hemodialysis Humans Kidney cancer Kidney disease Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - mortality Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Male Middle Aged Molecular Targeted Therapy - adverse effects mTOR inhibitors Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - adverse effects Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Renal Dialysis Retrospective Studies Sirolimus - adverse effects Sirolimus - analogs & derivatives Sirolimus - therapeutic use Sulfonamides - adverse effects Sulfonamides - therapeutic use Treatment Outcome Urology VEGF tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Data are limited regarding outcomes in patients with end-stage renal disease (ESRD) and metastatic renal cell carcinoma (mRCC) receiving targeted therapy. We retrospectively identified patients with mRCC and ESRD treated at the University of Texas M.D. Anderson Cancer Center from 2002 to 2012. Fourteen patients were identified with a median number of targeted therapies (TTs) per patient of 3 (range, 1-4). Outcomes in patients with mRCC and ESRD were similar to those reported in patients with normal kidney function.
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2014.01.004